We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Edwards Lifesciences (EW) Stock Moves -1.18%: What You Should Know
Read MoreHide Full Article
Edwards Lifesciences (EW - Free Report) closed the most recent trading day at $87.73, moving -1.18% from the previous trading session. This change was narrower than the S&P 500's daily loss of 3.25%. Meanwhile, the Dow lost 2.42%, and the Nasdaq, a tech-heavy index, lost 0.41%.
Heading into today, shares of the medical device maker had lost 4.96% over the past month, lagging the Medical sector's loss of 1.96% and outpacing the S&P 500's loss of 5.62% in that time.
Edwards Lifesciences will be looking to display strength as it nears its next earnings release. On that day, Edwards Lifesciences is projected to report earnings of $0.64 per share, which would represent no growth from the year-ago period. Meanwhile, our latest consensus estimate is calling for revenue of $1.4 billion, up 1.92% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $2.57 per share and revenue of $5.72 billion. These totals would mark changes of +15.77% and +9.29%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Edwards Lifesciences. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.13% higher within the past month. Edwards Lifesciences currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Edwards Lifesciences is currently trading at a Forward P/E ratio of 34.6. This valuation marks a premium compared to its industry's average Forward P/E of 26.42.
Meanwhile, EW's PEG ratio is currently 2.5. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Instruments industry currently had an average PEG ratio of 1.89 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 188, which puts it in the bottom 26% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Edwards Lifesciences (EW) Stock Moves -1.18%: What You Should Know
Edwards Lifesciences (EW - Free Report) closed the most recent trading day at $87.73, moving -1.18% from the previous trading session. This change was narrower than the S&P 500's daily loss of 3.25%. Meanwhile, the Dow lost 2.42%, and the Nasdaq, a tech-heavy index, lost 0.41%.
Heading into today, shares of the medical device maker had lost 4.96% over the past month, lagging the Medical sector's loss of 1.96% and outpacing the S&P 500's loss of 5.62% in that time.
Edwards Lifesciences will be looking to display strength as it nears its next earnings release. On that day, Edwards Lifesciences is projected to report earnings of $0.64 per share, which would represent no growth from the year-ago period. Meanwhile, our latest consensus estimate is calling for revenue of $1.4 billion, up 1.92% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $2.57 per share and revenue of $5.72 billion. These totals would mark changes of +15.77% and +9.29%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Edwards Lifesciences. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.13% higher within the past month. Edwards Lifesciences currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Edwards Lifesciences is currently trading at a Forward P/E ratio of 34.6. This valuation marks a premium compared to its industry's average Forward P/E of 26.42.
Meanwhile, EW's PEG ratio is currently 2.5. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Instruments industry currently had an average PEG ratio of 1.89 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 188, which puts it in the bottom 26% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.